Identification

Generic Name
Oxeladin
DrugBank Accession Number
DB04822
Background

Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 335.4809
Monoisotopic: 335.246043927
Chemical Formula
C20H33NO3
Synonyms
  • 2-(2-Diethylaminoethoxy)ethyl 2-ethyl-2-phenylbutyrate
  • Oxeladin
  • Oxeladina
  • Oxeladine
  • Oxeladinum

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Oxeladin citrate5AEV5C340C52432-72-1KVKJFNUGVOFNGU-UHFFFAOYSA-N

Categories

ATC Codes
R05DB09 — Oxeladin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Fatty acid esters / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Dialkyl ethers / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Amine / Amino acid or derivatives / Aromatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether / Ether / Fatty acid ester / Fatty acyl
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
SNC1080T5Y
CAS number
468-61-1
InChI Key
IQADUMSPOQKAAO-UHFFFAOYSA-N
InChI
InChI=1S/C20H33NO3/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4/h9-13H,5-8,14-17H2,1-4H3
IUPAC Name
2-[2-(diethylamino)ethoxy]ethyl 2-ethyl-2-phenylbutanoate
SMILES
CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
4619
PubChem Substance
46508573
ChemSpider
4458
RxNav
32626
ChEBI
135424
ChEMBL
CHEMBL1500276
ZINC
ZINC000003874580
Wikipedia
Oxeladin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)150 °C at 5.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0158 mg/mLALOGPS
logP4.62ALOGPS
logP4.43ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)9.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity98.97 m3·mol-1ChemAxon
Polarizability39.35 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9847
Blood Brain Barrier+0.9363
Caco-2 permeable+0.6538
P-glycoprotein substrateSubstrate0.6697
P-glycoprotein inhibitor INon-inhibitor0.6281
P-glycoprotein inhibitor IINon-inhibitor0.8685
Renal organic cation transporterNon-inhibitor0.6358
CYP450 2C9 substrateNon-substrate0.8558
CYP450 2D6 substrateNon-substrate0.889
CYP450 3A4 substrateNon-substrate0.5098
CYP450 1A2 substrateNon-inhibitor0.6155
CYP450 2C9 inhibitorNon-inhibitor0.9244
CYP450 2D6 inhibitorInhibitor0.9174
CYP450 2C19 inhibitorNon-inhibitor0.829
CYP450 3A4 inhibitorInhibitor0.677
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6412
Ames testNon AMES toxic0.8367
CarcinogenicityNon-carcinogens0.5665
BiodegradationNot ready biodegradable0.9781
Rat acute toxicity3.2320 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9043
hERG inhibition (predictor II)Inhibitor0.6033
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at September 11, 2007 20:25 / Updated at February 21, 2021 18:51